Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s ...
SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a ...
Revolution Medicines built a $4.3B liquidity wall around daraxonrasib. Inside its Phase 3 data, Royalty Pharma terms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results